Clinical Trials

Thyroid Carcinoma, Anaplastic

NCT04675710 2026-02-19

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Thyroid Carcinoma, Anaplastic

NCT04171622 2026-02-17

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

25 enrolled

Phase EARLY_PHASE1 Recruiting

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT06639191 2026-01-30

AKIR001

15 enrolled

EndocrineGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Vulvar Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

50 enrolled

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT03449108 2025-11-21

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT04759911 2025-11-13

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Thyroid Cancer, Papillary, Thyroid Neoplasms, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT06902376 2025-11-05

NEO-COMBATXL

Phase 1 Recruiting

12 enrolled

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05453799 2025-10-20

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

54 enrolled

Thyroid Carcinoma, Anaplastic

NCT06790706 2025-10-06

IMMUNORARE5

EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

154 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT07181720 2025-10-02

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Phase 1 Recruiting

90 enrolled

EndocrineGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thymoma, Thyroid Carcinoma, Anaplastic

NCT06374602 2025-09-05

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

20 enrolled

DermatologicEndocrineHead & NeckThoracic

Thyroid Carcinoma, Anaplastic

NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Phase 1 Suspended

71 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

NCT07138261 2025-08-22

TATC

Not yet recruiting

100 enrolled

Phase EARLY_PHASE1 Active not recruiting

Thyroid Carcinoma, Anaplastic

NCT03085056 2025-07-03

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

13 enrolled

Thyroid Carcinoma, Anaplastic

NCT04238624 2025-07-02

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

16 enrolled

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT04400474 2025-06-19

CABATEN

CNSEndocrineHead & NeckNET

93 enrolled 17 charts

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

NCT04552769 2025-06-05

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

9 enrolled 10 charts

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

87 enrolled 29 charts

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT04420754 2025-03-30

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Phase 1 Active not recruiting

70 enrolled

Recurrence, Thyroid Carcinoma, Anaplastic

NCT02152137 2025-01-27

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

19 enrolled 13 charts

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT06235216 2024-11-01

SETHY

42 enrolled

Thyroid Carcinoma, Anaplastic

NCT03565536 2024-04-19

Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

18 enrolled

Thyroid Carcinoma, Anaplastic

NCT06362694 2024-04-12

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

10 enrolled

Thyroid Carcinoma, Anaplastic

NCT04739566 2024-03-25

ANAPLAST-NEO

Phase 2 Withdrawn

Thyroid Carcinoma, Anaplastic

NCT03488134 2024-03-19

Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3

Completed

74 enrolled

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT02244463 2024-01-12

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Phase 1/2 Completed

46 enrolled 18 charts

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT06079333 2023-10-12

NEO-ATACT

20 enrolled

Thyroid Carcinoma, Anaplastic

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

206 enrolled 40 charts 4 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT05102292 2023-08-21

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Phase 1/2 Unknown

25 enrolled

Thyroid Carcinoma, Anaplastic

NCT04031339 2023-05-10

ITCO

15,000 enrolled

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT05819593 2023-04-19

Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences

Not yet recruiting

500 enrolled

Thyroid Carcinoma, Anaplastic

NCT05796960 2023-04-04

ATCEU

3,917 enrolled

BreastDermatologicEndocrineHead & NeckThoracic

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

319 enrolled 41 charts

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT01236547 2022-07-19

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

123 enrolled 24 charts

Thyroid Carcinoma, Anaplastic

NCT03122496 2022-06-08

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Phase 1 Completed

13 enrolled

Thyroid Carcinoma, Anaplastic

NCT02688608 2022-02-10

Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

6 enrolled 10 charts

Thyroid Carcinoma, Anaplastic

NCT02862470 2021-07-06

Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients

Completed

22 enrolled

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT01774279 2021-01-05

iNATT

350 enrolled

Thyroid Carcinoma, Anaplastic

NCT03896958 2020-12-04

PIONEER

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

1,000 enrolled

Adenocarcinoma of Lung, Adrenal Gland Neoplasms, Anus Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Neoplasms, Unknown Primary, Neurologic Manifestations, Oligodendroglioma, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Sarcoma, Skin Neoplasms, Stomach Neoplasms, Testicular Neoplasms, Uterine Neoplasms, Vulvar Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Phase 1 Terminated

5 enrolled

DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

NCT04574817 2020-10-05

Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

Phase 2 Unknown

66 enrolled

Thyroid Carcinoma, Anaplastic

NCT00603941 2020-09-16

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Phase 1/2 Terminated

19 enrolled 13 charts

Neoplasms, Thyroid Carcinoma, Anaplastic

NCT02726503 2020-06-17

HOPE

39 enrolled